Amarin Co. plc (NASDAQ:AMRN - Get Free Report) shares crossed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $10.40 and traded as high as $11.20. Amarin shares last traded at $11.18, with a volume of 77,915 shares traded.
Analysts Set New Price Targets
Several research analysts have weighed in on the stock. The Goldman Sachs Group dropped their price objective on shares of Amarin from $20.00 to $7.00 and set a "sell" rating on the stock in a research note on Thursday, April 17th. StockNews.com started coverage on Amarin in a research report on Wednesday, April 16th. They issued a "sell" rating on the stock.
Read Our Latest Stock Analysis on AMRN
Amarin Price Performance
The company's 50 day moving average price is $9.54 and its 200 day moving average price is $10.36. The firm has a market capitalization of $220.95 million, a P/E ratio of -119.56 and a beta of 1.38.
Amarin (NASDAQ:AMRN - Get Free Report) last issued its earnings results on Wednesday, March 12th. The biopharmaceutical company reported ($2.40) EPS for the quarter, missing the consensus estimate of ($1.20) by ($1.20). Amarin had a negative net margin of 16.33% and a negative return on equity of 7.22%. The business had revenue of $62.31 million for the quarter, compared to the consensus estimate of $32.37 million. On average, research analysts anticipate that Amarin Co. plc will post -0.15 EPS for the current fiscal year.
Institutional Investors Weigh In On Amarin
Several hedge funds have recently added to or reduced their stakes in AMRN. New York State Common Retirement Fund acquired a new stake in Amarin in the fourth quarter valued at about $68,000. Waterfront Wealth Inc. boosted its position in shares of Amarin by 181.4% during the 4th quarter. Waterfront Wealth Inc. now owns 2,481,766 shares of the biopharmaceutical company's stock worth $1,204,000 after purchasing an additional 1,599,956 shares in the last quarter. Arkfeld Wealth Strategies L.L.C. raised its holdings in Amarin by 52.6% during the fourth quarter. Arkfeld Wealth Strategies L.L.C. now owns 58,000 shares of the biopharmaceutical company's stock worth $30,000 after buying an additional 20,000 shares during the last quarter. LCM Capital Management Inc grew its holdings in Amarin by 3.1% during the fourth quarter. LCM Capital Management Inc now owns 838,259 shares of the biopharmaceutical company's stock worth $407,000 after buying an additional 25,100 shares in the last quarter. Finally, Stonepine Capital Management LLC bought a new position in shares of Amarin during the 4th quarter worth approximately $55,000. Institutional investors and hedge funds own 22.25% of the company's stock.
About Amarin
(
Get Free Report)
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
Further Reading
Before you consider Amarin, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amarin wasn't on the list.
While Amarin currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
